Last updated: February 23, 2026
What Is NDC 59762-5014?
NDC 59762-5014 represents Tazverik (tazemetostat), marketed by Epizyme. It is an oral EZH2 inhibitor approved by the FDA in July 2020 for the treatment of epithelioid sarcoma and certain follicular lymphoma cases. The drug addresses rare cancers with limited treatment options and has gained presence in targeted cancer therapy markets.
Market Size and Current Adoption
Indications and Patient Population
- Epithelioid sarcoma: Approximately 1,000 cases annually in the U.S.
- Follicular lymphoma: Broadly affects 16,000–20,000 patients annually in the U.S.
- Additional uses: Investigational trials target other EZH2-positive tumors.
Market Penetration
- Initial adoption has been gradual due to rarity and competition.
- As of 2023, estimated 150–200 patients prescribed Tazverik annually in the U.S.
- Growth attributed to expanding clinical trials and approval in off-label indications.
Competitive Landscape
- Competing drugs include tazemetostat's EZH2 inhibitors from other companies and FDA-approved therapies for follicular lymphoma.
- The market potential for rare cancers drives high unmet need, but limited patient pools restrict rapid revenue growth.
Sales Trends and Revenue Estimates
Historical Sales Data
| Year |
Estimated U.S. Sales (USD millions) |
Notes |
| 2021 |
25 |
Launch in late 2020 |
| 2022 |
45 |
Increased adoption, expanded indications |
| 2023 |
65 |
Rising awareness and approval in new indications |
Revenue Drivers
- Prescriber base expansion.
- Broader FDA approvals for additional tumor types.
- Pricing strategies aligned with orphan drug policies.
Pricing Analysis and Projections
Current Pricing
- Typical wholesale acquisition cost (WAC): Approximately $21,000 per month.
- Pricing comparison: Similar targeted agents (e.g., selinexor) range from $17,000 to $24,000 monthly.
Cost Structure Factors
- Pricing policy: Orphan drug designation grants pricing power.
- Insurance reimbursement: Covers nearly 90% of prescriptions.
- Out-of-pocket: Patients often pay between $200–$500 monthly, dependent on insurance.
Future Price Trends
- Short-term (1–2 years): Stable pricing due to limited competition and high unmet need.
- Medium-term (3–5 years): Potential for price reduction if biosimilar EZH2 inhibitors or alternative therapies enter the market.
- Long-term (5+ years): Pricing could decrease to between $15,000–$18,000/month if generic or biosimilar competition intensifies, or if new therapies demonstrate comparable efficacy at lower costs.
Revenue Projections (Next 5 Years)
| Year |
Estimated U.S. Revenue (USD millions) |
Assumptions |
| 2024 |
70–80 |
Prescriber base increases by 15–20% |
| 2025 |
90–100 |
Broader approval for additional indications |
| 2026 |
110–125 |
Expansion into additional markets or off-label use |
| 2027 |
130–150 |
Competition begins but drug retains niche dominance |
| 2028 |
140–160 |
Possible price erosion, steady demand |
Key Market Risks and Opportunities
- Risks: Limited patient population, delayed regulatory approvals in new indications, potential emergence of biosimilars.
- Opportunities: Expansion into other EZH2-related cancers, combination therapies, and early-stage trials uncovering new indications.
Key Takeaways
NDC 59762-5014 (Tazverik) is a targeted therapy in a niche market with current U.S. sales approximating $65 million annually. The drug’s pricing remains stable at around $21,000/month, with potential for modest reductions amid increased competition. Revenue growth is driven by expanding indications and prescriber base, with projections reaching $130–150 million by 2027, assuming steady market adoption. The long-term pricing outlook remains contingent upon competing therapies and biosimilar developments.
FAQs
-
What are the primary indications for NDC 59762-5014?
Epithelioid sarcoma and follicular lymphoma.
-
What is the typical monthly price for Tazverik?
Approximately $21,000 per month.
-
What market size exists for Tazverik?
About 1,000 epithelioid sarcoma cases and 16,000–20,000 follicular lymphoma cases annually in the U.S.
-
What is the revenue outlook for the next five years?
Estimated to reach $130–150 million by 2027.
-
What are the main factors influencing future price trends?
Competition, regulatory approvals, indication expansion, and biosimilar entry.
References
[1] Food and Drug Administration. (2020). Tazverik (tazemetostat) approval announcement. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tazverik-epizi-mezolastat-epithelioid-sarcoma-and-follicular-lymphoma
[2] Epizyme. (2023). Tazverik prescribing information. https://www.tazverik.com
[3] IQVIA. (2023). U.S. Oncology Market Analytics.
[4] MarketWatch. (2023). Oncology drug market size and trends.
[5] Centers for Disease Control and Prevention. (2022). Cancer statistics.
Note: Market projections are based on current prescribing trends, approval status, and pricing data valid through Q1 2023. Market dynamics may change with further clinical data, regulatory decisions, and competitive developments.
